ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1834

Total Hip Arthroplasty Outcomes: A 17 Year Experience in a Single-Center: Is Systemic Lupus Erythematosus a Real Risk Factor for Adverse Outcomes?

Marco González-Contreras1, Javier Merayo-Chalico1, Rigoberto Ortíz-Hernández2, Diana Gómez-Martín2 and Jorge Alcocer-Varela2, 1Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Arthroplasty and systemic lupus erythematosus (SLE), Hip

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: In patients with systemic lupus erythematosus (SLE), persistent joint activity and treatment with glucocorticoids are associated with musculoskeletal complications, including hip osteonecrosis. About 30% of these patients develop disability and become candidates for surgical treatment. The frequency of total hip arthroplasty (THA) in these patients has increased progressively. The aim of this study was to evaluate postoperative outcomes and potential risk factors for complications after THA in SLE patients in comparison to other inflammatory and non-inflammatory diseases. 

Methods: We performed a retrospective cohort study at a tertiary care center in Mexico City between 1995 and 2013. All patients with SLE (ACR criteria ≥4), who underwent THA were included (n=58). They were compared with a group of patients with rheumatoid arthritis (RA) and other group with osteoarthritis (OA), matched by gender and date of surgery. All surgeries were performed by the same surgical team. The main outcome was frequency of any postoperative complication during follow-up. The assessed complications were: transfusion requirement, hematoma, thrombosis, infections, aseptic loosening and prosthesis dislocation.

Results: We included 174 patients that underwent THA during the study period. The surgical indication was avascular necrosis in most patients with SLE and RA (98%). Univariate analysis revealed that patients with SLE were younger (p<0.001), and had a longer hospitalization (p=0.001), as well as more transfusional requirements (p=0.004). Other variables are shown in Table 1. Global complications in THA in patients with SLE were more prevalent than in the other groups (36% vs 9%, p<0.001). Most of these events occurred during the postoperative hospitalization. After multivariate analysis, risk factors for THA complications were: SLE (HR 2.8, 95%CI 1.2-6.8; p=0.018) and low postoperative hemoglobin (HR 0.77, 95%CI 0.73-0.83; p<0.001). There was a trend towards a higher risk of complications in patients with history of glucocorticoid treatment (p=0.055). Long-term complications after THA were not different among groups.

Conclusion: To our knowledge, this is the largest single-center study regarding the clinical outcomes after THA in SLE patients. Our data suggest that SLE is an independent risk factor for adverse postoperative outcomes, mainly immediate complications. Particular emphasis should be made on attaining optimal postoperative hemoglobin levels after THA in SLE patients. Our data suggest that even though SLE is associated with increased risk of immediate complications, the long term outcome is good enough to offer surgical treatment, such as THA, that will eventually improve quality of life. 

Table 1 Baseline demographic, clinical and laboratory characteristics in patients with total hip arthroplasty

Variables (mean±SEM)

Total hip arthroplasty in SLE

(n=58)

Total hip arthroplasty in RA/OA

(n=116)

Age, [years]

34.4 ± 1.05

55.1 ± 1.47

SLEDAI, [points]

1.31 ± 0.32

N/A

Preoperative glucocorticoid dose [mg/day]

2.1 ± 0.49

0.3 ± 0.12

Cumulative glucocorticoid dose [mg/year]

755.1 ± 160.49

125.8 ± 47.26

Postoperative hemoglobin [gr/dL]

9.0 ± 0.23

9.6 ± 0.12

Transoperative transfusion requirements (%)

 

19/58 (32.7)

8/156 (6.8)

Hospitalization length, [days]

11.3 ± 0.86

8.2 ± 0.13

Global complications (%)

  • Immediate (same hospitalization period as the surgical event)
  • Mediate
  • Late (≥30 days after hospital discharge)

21/58 (36.2)

17/58 (29.3)

0

4/58 (6.8)

11/116 (9.4)

10/116 (8.6)

0

1 (0.68)

 Values in bold are statistical significant (p <0.05)


Disclosure: M. González-Contreras, None; J. Merayo-Chalico, None; R. Ortíz-Hernández, None; D. Gómez-Martín, None; J. Alcocer-Varela, None.

To cite this abstract in AMA style:

González-Contreras M, Merayo-Chalico J, Ortíz-Hernández R, Gómez-Martín D, Alcocer-Varela J. Total Hip Arthroplasty Outcomes: A 17 Year Experience in a Single-Center: Is Systemic Lupus Erythematosus a Real Risk Factor for Adverse Outcomes? [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/total-hip-arthroplasty-outcomes-a-17-year-experience-in-a-single-center-is-systemic-lupus-erythematosus-a-real-risk-factor-for-adverse-outcomes/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/total-hip-arthroplasty-outcomes-a-17-year-experience-in-a-single-center-is-systemic-lupus-erythematosus-a-real-risk-factor-for-adverse-outcomes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology